1. NIH in Danger of Losing Out on
BRCA1
Patent
2. Compared to today's astronomical prices for the latest gene therapy treatments, some of which can exceed $2 million, the $8,000 price tag for AZT seems quaint. Yet, at the time, the New York Times called AZT "the most expensive prescription drug in history;Lauran Neergaard;NIH Drops 'Reasonable Price' Clause for Drug Company Collaboration, ASSOCIATED PRESS,1989
3. Over the years, NIH has exhibited a surprising reluctance to seek distributional and access goals for federally-funded technologies, particularly its never-asserted "march-in" rights under the Bayh-Dole Act;Marlene Cimons;TIMES,1989
4. Genes and Patent Policy: Rethinking Intellectual Property Rights, 3 NATURE REV;Lori B Andrews;GENETICS,2002